Table 2.
Antimicrobial resistance profiles of urinary E. coli and Klebsiella spp. isolates in accordance with major epidemiological groups.
| Criteria | AMP | AMC | CIP | SXT | AK | CRO | CTX | CAZ | TZP | ETP | MEM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| All isolates N: 97 |
91/96 94.8% |
63/95 66.3% |
57/97 58.8% |
56/93 60.2% |
21/93 22.6% |
62/94 66% |
56/89 62.9% |
61/97 62.9% |
21/96 21.9% |
12/96 12.5% |
8/97 8.2% |
| ESBL (p-value) | 0.001 | 0.001 | 0.001 | 0.003 | 0.002 | 0.001 | 0.001 | 0.001 | 0.001 | 0.013 | 0.048 |
| Yes (n = 67) | 67/67 100% |
53/65 81.5% |
49/67 73.1% |
46/66 69.7% |
20/63 31.7% |
61/64 95.3% |
55/59 93.2% |
59/67 88% |
21/66 31.8% |
12/66 18.2% |
8/67 11.9% |
| No (n = 30) | 24/29 82.8% |
10/30 33.3% |
8/30 26.7% |
10/27 37% |
1/30 3.3% |
1/30 3.3% |
1/30 3.3% |
2/30 6.6% |
0/30 0% |
0/30 0% |
0/30 0% |
| Hospital-acquired UTI (p-value) | 0.14 | 0.83 | 0.875 | 0.137 | 0.677 | 0.559 | 0.217 | 0.259 | 0.179 | 0.045 | 0.021 |
| Yes (n = 47) | 42/46 91.3% |
31/46 67.4% |
28/47 60% |
30/44 68.2% |
11/45 24.4% |
29/46 63% |
26/47 55.3% |
30/47 63.8% |
13/47 27.7 |
9/46 19.6% |
7/47 14.9% |
| No (n = 50) | 49/50 98% |
32/49 65.3% |
29/50 58% |
26/49 53.1% |
10/48 20.8% |
33/48 68.7% |
30/50 60% |
31/50 62% |
8/49 16.3% |
3/50 6% |
1/50 2% |
| Prior recurrent UTI (p-value) | 0.514 | 0.217 | 0.312 | 0.583 | 0.178 | 0.028 | 0.219 | 0.070 | 0.421 | 0.757 | 0.831 |
| Yes (n = 52) | 50/52 96.2% |
36/50 72% |
33/52 63.5% |
32/51 62.7% |
14/50 28% |
38/50 76% |
33/52 63.5% |
37/52 71.2% |
13/52 25% |
7/52 13.5% |
4/52 7.7% |
| No (n = 45) | 41/44 93.2% |
27/45 60% |
24/45 53.3% |
24/42 57.1% |
7/43 16.3% |
24/44 54.5% |
23/45 51.1% |
24/45 53.3% |
8/44 18.2% |
5/44 11.4% |
4/45 8.9% |
AMP, ampicillin; AMC, amoxicillin/clavulanic acid; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; AK, amikacin; CRO, ceftriaxone; CTX, cefotaxime; CAZ, ceftazidime; TZP, piperacillin/tazobactam; ETP, ertapenem; MEM, meropenem. Bold values represent the statistically significant results.